Skip to main content
. 2010 Jul 14;31(9):1567–1575. doi: 10.1093/carcin/bgq147

Fig. 1.

Fig. 1.

Expression of EZH2 and RUNX3 in CRC cell lines and CRC patient specimens. (A) Immunoblots of colon cancer cell lines for EZH2 and RUNX3 with actin as a loading control. (B) Methylation-specific PCR (MSP) analysis of the CpG island methylation status of the RUNX3 promoter region in CRC cell lines. PCR products specific for unmethylated (U) and methylated (M) CpG sites were analysed in 2.5% agarose gels. (C) Positive nuclear expression of EZH2 and RUNX3 in HCT116 and SW480 CRC cell lines by immunofluorescence. (D) Quantitative RT–PCR analysis of EZH2 and RUNX3 expression in CRC cell lines. (E) Quantitative RT–PCR analysis of EZH2 (linear scale) and RUNX3 expression (log10 scale) in CRC patients. (F) MSP for RUNX3 promoter region MSP in a subgroup of CRC patients. T1–T5 shows positive methylated and unmethylated signals, whereas T6–T8 shows only an unmethylated band.